Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
European Journal of Orthopaedic Surgery & Traumatology
Erschienen in: European Journal of Orthopaedic Surgery & Traumatology 5/2013

01.07.2013 | Original Article

Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population

verfasst von: Zhi-han Li, Yang Zhang, Jian Wang, Zhan-jun Shi

Erschienen in: European Journal of Orthopaedic Surgery & Traumatology | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

Ankylosing spondylitis (AS) is a kind of rheumatic disease, leading to pain, fatigue, stiffness, and functional impairment, which seriously affects the quality of life. Etanercept, a fully human recombinant protein, has been applied for the treatment of AS. However, there has not been a systematic analysis for its efficacy and safety.

Methods

This meta-analysis of fourteen randomized, double-blind, placebo-controlled clinical trials with 1,570 participants was performed to investigate the efficacy and safety of etanercept, by means of calculating the overall relative risk, and to compare the different responses between the Caucasian population and the Chinese population.

Results

Generally, there was sufficient evidence to prove that etanercept has its advantages in both disease activity controlling and symptoms relieving, especially for axial joints compared with peripheric joints, without higher incidence of serious adverse events.

Interpretation

Our preliminary analysis provided that the Caucasian population has better response to etanercept treatment, with more treatment-emergent adverse events. Further specially designed clinical trials need to be performed to investigate the different responses between axial and peripheric joints, also between different races.
Literatur
1.
Braun J, Khan MA, Sieper J (2000) Enthesitis and ankylosis in spondyloarthropathy: what is the target of the immune response? Ann Rheum Dis 59:985–994PubMedCrossRef
2.
Braun J, Bollow M, Sieper J (1998) Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am 24:697–735PubMedCrossRef
3.
Carter ET, McKenna CH, Brian DD, Kurland LT (1979) Epidemiology of ankylosing spondylitis in Rochester, Minnesota, 1935–1973. Arthritis Rheum 22:365–370PubMedCrossRef
4.
Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J (2003) Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 23:61–66PubMed
5.
Ward MM, Reveille JD, Learch TJ, Davis JC Jr, Weisman MH (2008) Occupational physical activities and long-term functional and radiographic outcomes in patients with ankylosing spondylitis. Arthritis Rheum 59:822–832PubMedCrossRef
6.
Ward MM, Reveille JD, Learch TJ, Davis JC Jr, Weisman MH (2008) Impact of ankylosing spondylitis on work and family life: comparisons with the US population. Arthritis Rheum 59:497–503PubMedCrossRef
7.
Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B et al (2006) ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65:442–452PubMedCrossRef
8.
Toussirot E, Wendling D (1998) Current guidelines for the drug treatment of ankylosing spondylitis. Drugs 56:225–240PubMedCrossRef
9.
Arend WP (2002) The mode of action of cytokine inhibitors. J Rheumatol Suppl 65:16–21PubMed
10.
Fernandez-Botran R (2000) Soluble cytokine receptors: novel immunotherapeutic agents. Expert Opin Investig Drugs 9:497–514PubMedCrossRef
11.
Gratacós J, Collado A, Filella X, Sanmartí R, Cañete J, Llena J, Molina R, Ballesta A, Muñoz-Gómez J (1994) Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 33(10):927–931PubMedCrossRef
12.
Francois RJ, Neure L, Sieper J, Braun J (2006) Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumor necrosis factor in two patients with early disease and transforming growth factor in three more advanced cases. Ann Rheum Dis 65:713–720PubMedCrossRef
13.
Fernandez-Botran R (2000) Soluble cytokine receptors: novel immunotherapeutic agents. Expert Opin Investig Drugs 9:497–514PubMedCrossRef
14.
Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48(6):1667–1675PubMedCrossRef
15.
Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187–1193PubMedCrossRef
16.
Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R et al (2005) Persistent clinical response to the anti-TNF-α antibody infliximab in patients with ankylosing spondylitis over 3 years. Heumatology 44:670–676
17.
Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G et al (2008) Persistent clinical efficacy and safety of anti-tumour necrosis factor therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 67:340–345PubMedCrossRef
18.
Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, Enbrel Ankylosing Spondylitis Study Group (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48(11):3230–3236PubMedCrossRef
19.
Davis JC Jr, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ et al (2008) Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 67:346–352PubMedCrossRef
20.
Haibel H, Rudwaleit M, Brandt HC, Grozdanovic Z, Listing J, Kupper H et al (2006) Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 54:678–681PubMedCrossRef
21.
Barkham N, Coates LC, Keen H, Hensor E, Fraser A, Redmond A, Cawkwell L, Emery P (2010) Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis 69(11):1926–1928 Epub 2010 May 28PubMedCrossRef
22.
Van der Heijde D, Landewé R, Einstein S, Ory P, Vosse D, Ni L, Lin SL, Tsuji W, Davis JC Jr (2008) Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 58(5):1324–1331PubMedCrossRef
23.
Rychly DJ, Dipiro JT (2005) Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 25(9):1181–1192PubMedCrossRef
24.
Askling J, Forted CM, Baecklund E et al (2005) Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumor necrosis factor antagonists. Ann Rheum Dis 64(10):1414–1420PubMedCrossRef
25.
Moher D, Cook DJ, Eastwood S et al (1999) Improving the quality of reports of meta-analysis of randomised controlled trials: the QUOROM statement. Lancet 354:1896–1900PubMedCrossRef
26.
Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12PubMedCrossRef
27.
Higgins JPT, Green S (2008) Cochrane handbook for systematic reviews of interventions version 5.0.1 [updated September 2008]. The Cochrane Collaboration
28.
Simunovic N, Sprague S, Bhandari M (2009) Methodological issues in systematic reviews and meta-analyses of observational studies in orthopaedic research. J Bone Joint Surg [Am] 91:87–94CrossRef
29.
Gorman JD, Sack KE, Davis JC Jr (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346(18):1349–1356PubMedCrossRef
30.
Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M et al (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63(12):1594–1600PubMedCrossRef
31.
Dougados M, Braun J, Szanto S, Combe B, Elbaz M, Geher P et al (2011) Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis 70(5):799–804PubMedCrossRef
32.
Van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X et al (2006) Etanercept study 314 investigators. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 65(12):1572–1577PubMedCrossRef
33.
Huang Feng, Zhang Jie, Huang JL, Wu DH, Li ZG, Chen SL et al (2010) A multicenter, double-blind, placebo-controlled, randomized, phase III clinical study of etanercept in treatment of ankylosing spondylitis. Chin J Intern Med 49(9):741–745
34.
Maksymowych WP, Poole AR, Hiebert L, Webb A, Ionescu M, Lobanok T et al (2005) Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 32(10):1911–1917PubMed
35.
Wanders AJ, Gorman JD, Davis JC, Landewe RB, van der Heijde DM (2004) Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis. Arthritis Rheum 51(1):1–8PubMedCrossRef
36.
Wang LS, Huang F, Zhang JL, Deng XH, Zhang YM, Zhang LY et al (2007) A cohort analysis of safety tumor necrosis factor-α antagonists in the treatment of Chinese patients with ankylosing spondylitis. Chin J New Drugs 16(7):556–561
37.
Zhang H, Deng XH, Zhang YM, Zhang JL, Huang F (2008) Studies on safety of etanercept in treatment of ankylosing spondylitis. Adverse Drug React J 10(6):396–399
38.
Zhang YM, Li XL, Wu HL, Zhang J (2009) Short-term safety of etanercept therapy in patients with ankylosing spondylitis. Chin J Drug Appl Monit 6(1):4–13
39.
Zhang J (2010) Initiatory approach on clinical assessment and evaluation of etanercept in the treatment of ankylosing spondylitis. Graduation dissertation for Master’s degree
40.
Braun J, Golder W, Bollow M, Sieper J, van der Heijde D (2002) Imaging and scoring in ankylosing spondylitis. Clin Exp Rheumatol 20:S178–S184PubMed
41.
Brandt J, Listing J, Haibel H, Sörensen H, Schwebig A, Rudwaleit M et al (2005) Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology 44(3):342–348PubMedCrossRef
42.
Baraliakos X, Brandt J, Listing J, Haibel H, Sorensen H, Rudwaleit M et al (2005) Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 53:856–863PubMedCrossRef
43.
Baraliakos X, Davis J, Tsuji W, Braun J (2005) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor receptor fusion protein etanercept. Arthritis Rheum 52:1216–1223PubMedCrossRef
44.
Braun J, Landewe R, Hermann KG, Han J, Yan S, Williamson P, for the ASSERT Study Group et al (2006) Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 54:1646–1652PubMedCrossRef
45.
McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, et al (2007) Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 11(28):1–158, iii–iv
Metadaten
Titel
Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population
verfasst von
Zhi-han Li
Yang Zhang
Jian Wang
Zhan-jun Shi
Publikationsdatum
01.07.2013
Verlag
Springer-Verlag
Erschienen in
European Journal of Orthopaedic Surgery & Traumatology / Ausgabe 5/2013
Print ISSN: 1633-8065
Elektronische ISSN: 1432-1068
DOI
https://doi.org/10.1007/s00590-012-1035-7

Weitere Artikel der Ausgabe 5/2013

European Journal of Orthopaedic Surgery & Traumatology 5/2013 Zur Ausgabe

Original Article

Latissimus dorsi flap coverage of soft tissue defect following below-knee amputation: emphasis on flap design and recipient vessels

Original Article

Modified retrograde percutaneous intramedullary multiple Kirschner wire fixation for treatment of unstable displaced metacarpal neck and shaft fractures

Original Article

Traumatic and non-traumatic isolated horizontal meniscal tears of the knee in patients less than 40 years of age

Original Article

Platelet-rich plasma (PRP) injections as an effective treatment for early osteoarthritis

Original Article

Intramedullary nailing versus percutaneous locked plating of distal extra-articular tibial fractures: a retrospective study

Original Article

Management of forearm deformities with ulnar shortening more than 15 mm caused by hereditary multiple osteochondromas

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Knie-TEP: Kein Vorteil durch antibiotikahaltigen Knochenzement

29.05.2024 Periprothetische Infektionen Nachrichten

Zur Zementierung einer Knie-TEP wird in Deutschland zu über 98% Knochenzement verwendet, der mit einem Antibiotikum beladen ist. Ob er wirklich besser ist als Zement ohne Antibiotikum, kann laut Registerdaten bezweifelt werden.

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise